Huntington’s disease (HD) chorea progressively limits patients’ lives1

As HD chorea progresses, movements become more frequent and appear throughout the body, interfering with activities of daily living and causing patients to become dependent on their carepartners.1

According to a real-world study that surveyed patients with Huntington's disease, those with chorea required self-care and mobility assistance across many areas of daily life, including2:

Getting dressed/


Use of a cane/
walking stick

Mobility support from friends and family

99% of patients with HD chorea required assistance with self-care activities2

By treating HD chorea early, you can make a difference in
patients’ lives3,4

In a survey conducted by the Huntington’s Disease Society of America (HDSA), carepartners cited chorea as the most impactful symptom of HD5

Most patients and carepartners state that it is “very important” to manage chorea; their concerns include loss of independence, unpredictability/uncontrollability, and impact on family life.3,4

No clinical trials have been conducted to demonstrate that treating HD chorea affects the outcomes listed above.

Management of chorea may be met with many challenges

There are a limited number of FDA-approved treatment options available for Huntington's disease chorea.6,7

Limitations of tolerability6,7

  • Medications may have dose-limiting side effects
  • Treatment of chorea should be determined individually as a balance of chorea reduction and
    medication tolerability

Severity of chorea7

  • Chorea severity may vary over the course of the disease

Prevalence of depression and suicidality in Huntington's disease

  • The lifetime prevalence of major depression in people with HD is about 40%8
  • Suicide rates range from approximately 5% to 13%9
  • 25% of patients attempt suicide10

Concomitant medications8

  • Some prescription medications may worsen voluntary motor control

Watch as Eileen discusses how HD chorea has impacted her life, and in particular, her work

REFERENCES: 1. Roos RAC. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5:40. doi:10.1186/1750-1172-5-40 2. Claassen DO, DeCourcy J, Mellor J, Johnston C, Iyer RG. Impact of chorea on self-care activity, employment, and health-care resource use in patients with Huntington’s disease. J Health Econ Outcomes Res. 2021;8(1):99-105. 3. Beglinger LJ, O’Rourke JJF, Wang C, Langbehn DR, Duff K, Paulsen JS; Huntington Study Group Investigators. Earliest functional declines in Huntington disease. Psychiatry Res. 2010;178(2):414-418. 4. Thorley EM, Iyer RG, Wicks P, et al. Understanding how chorea affects health-related quality of life in Huntington disease: an online survey of patients and caregivers in the United States. Patient. 2018;11(5):547-559. 5. Simpson JA, Lovecky D, Kogan J, Vetter LA, Yohrling GJ. Survey of the Huntington’s disease patient and caregiver community reveals most impactful symptoms and treatment needs. J Huntingtons Dis. 2016;5(4):395-403. 6. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 7. Burgess JC, Davis B, Fogarty E, et al. Caregiver Guide for Mid to Late Stage Huntington Disease: For Long-Term Care Facilities and In-Home Care Agencies. Huntington Disease Society of America; 2014. 8. Nance M, Paulsen J, Rosenblatt A, Wheelock V. A Physician’s Guide To The Management Of Huntington’s Disease. 3rd ed. New York: Huntington’s Disease Society of America; 2011 9. Wetzel HH, Gehl CR, Dellefave-Castillo L, et al. Suicidal ideation in Huntington disease: the role of comorbidity. Psychiatry Res. 2011;188(3):372-376. 10. Killoran A, Biglan KM. Current therapeutic options for Huntington’s disease: good clinical practice versus evidence-based approaches? Mov Disord. 2014;29(11):1404-1413. 11. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.